Celularity Case Studies

BIOVANCE®

Chronic 4th interspace wound treatment with BIOVANCE

CHRISTOPHER CORWIN, DPM, MS, FACFAS - JOHNS CREEK, GA

"BIOVANCE used to augment wound healing and also to reduce likelihood of recurrent ulceration through regenerative healing"

Patient Background

Female | Age: 65

Lupus

Chronic 4th interspace wound

PRESENTATION

Background:	Patient with history of lupus presented with a chronic 4th interspace wound. Flareup of the wound was noted in the same area over the previous year.
Initial Treatment:	• Incision & Drainage (I & D) with packing for 48 hours • IV antibiotics
Findings/Studies:	• No osteomyelitis
Supportive Treatment:	• Applied negative pressure wound therapy (NPWT) at 75 mm Hg • Patient discontinued use of NPWT after 10 days • Patient placed in surgical shoe for offloading



Female with chronic 4th interspace wound

TREATMENT STRATEGY

- Debrided non-viable tissue and administered IV antibiotics to manage infection
- Used BIOVANCE and NPWT to get wound closure and to fill the defect that had been a chronic problem for over a year in the 4th interspace
- Patient to use surgical shoe with non-adherent dressing and gauze
- Wound was monitored every 2 weeks for size



Post I&D with BIOVANCE application

TREATMENT OUTCOMES COMMENTS

- After initial application of BIOVANCE, wound did not stall, it improved every week
- Did not need a re-application of BIOVANCE
- Wound progressed to full healing in 77 days
- Good mobility of skin at the wound level which should translate to less likelihood of future recurrent ulceration
- No major safety concerns were observed



Post-Op approx. 1 month


Post-Op approx. 2.5 months

INDICATIONS FOR USE

BIOVANCE is an allograft intended for use as a biological membrane covering that provides the extracellular matrix while supporting the repair of damaged tissue. As a barrier membrane, BIOVANCE is intended to protect the underlying tissue and preserve tissue plane boundaries with minimized adhesion or fibrotic scarring. Indications include, but are not limited to, surgical covering, wrap or barrier, application to partial- and full-thickness, acute and chronic wounds (such as, traumatic and complex wounds, burns, surgical and Mohs surgery sites; and diabetic, venous, arterial, pressure and other ulcers), including wounds with exposed tendon, muscle, bone or other vital structures.

CONTRAINDICATIONS, WARNINGS, AND PRECAUTIONS

BIOVANCE is contraindicated in patients with a known hyper-sensitivity to BIOVANCE. If a patient has an adverse reaction related to the use of BIOVANCE, immediately discontinue its use. BIOVANCE should not be used on clinically infected wounds.

The pouch contents are sterile if the pouch is unopened and undamaged. Do not use if package seal is broken. Discard material if mishandling has caused possible damage or contamination. Do not resterilize.

BIOVANCE must be used prior to the expiration date on the product pouch. BIOVANCE should not be used together with a collagenase product on the wound.

Please refer to the BIOVANCE Package Insert for complete product information.

For product information, product complaints, or adverse reaction reporting, call 1-844-963-2273.

For more information, please contact Celularity at 1-844-963-2273 or visit www.biovance.net

celularity

BIOVANCE® and Celularity are registered trademarks of Celularity, Inc.
© 2019 Celularity, Inc. All rights reserved. BIO-2019-012 August 2019